NASDAQ · Analyst Forecast

Prelude Therapeutics Incorporated (PRLD) Stock Forecast & Price Target

$3.30 NASDAQ: PRLD Market Cap $190.71M

Price as of Nov 17, 2026 (intraday, delayed) · Analyst estimates retrieved Nov 17, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)

Revenue and earnings estimates published by analysts covering Prelude Therapeutics Incorporated (PRLD), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.

For Prelude Therapeutics Incorporated, analysts forecast revenue rising from $17.50M in 2025 to $100.00M in 2030; the average estimate for 2030 earnings per share is $0.64; with published estimates ranging from $0.24 to $1.86; 4 analysts contribute to these figures. These are forecasts published by analysts, not results.

Analyst price targets

MeasureValue
Current priceWhat the share trades at now.$3.30
Consensus targetThe average of the price targets analysts have published.$8.00
Median targetThe middle target, less affected by a single outlier.$8.00
Highest targetThe most optimistic published target.$8.00
Lowest targetThe most pessimistic published target.$8.00
Difference from priceHow far the consensus target sits from today’s price.+142.4%

A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.

Revenue forecast (USD)

The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.

YearLowAverageHighAnalysts
2025$17.11M$17.50M$17.89M2
2026$20.94M$20.95M$20.96M4
2027$29.32M$39.10M$48.88M3
2028$51.85M$100.00M$246.78M2
2029$51.85M$100.00M$246.78M1
2030$51.85M$100.00M$246.78M1

Earnings per share forecast

YearLowAverageHighAnalysts
2025−$3.64−$1.25−$0.472
2026−$0.60−$0.56−$0.534
2027−$0.53−$0.49−$0.453
2028−$0.61−$0.10$0.412
2029$0.08$0.22$0.641
2030$0.24$0.64$1.861

Prelude Therapeutics Incorporated (PRLD) forecast — frequently asked questions

What is the analyst price target for Prelude Therapeutics Incorporated?

Analysts covering Prelude Therapeutics Incorporated (PRLD) have a consensus price target of $8.00, 142.4% above the current price of $3.30. Published targets range from $8.00 to $8.00. A price target is a forecast, not a measure of value, and targets are revised often.

What are analysts forecasting for Prelude Therapeutics Incorporated's earnings?

The average analyst estimate for Prelude Therapeutics Incorporated (PRLD) earnings per share in 2030 is 0.64, with individual estimates between 0.24 and 1.86.

How much revenue is Prelude Therapeutics Incorporated expected to make?

Analysts forecast Prelude Therapeutics Incorporated (PRLD) revenue of $100.00M in 2030, based on 1 published estimates.

How many analysts cover PRLD?

4 analysts contribute estimates for Prelude Therapeutics Incorporated (PRLD). Thin coverage makes an average less reliable.

Analyst forecasts for other Biotechnology stocks

VRTX forecastREGN forecastMRNA forecastRVMD forecastROIV forecastINSM forecastUTHR forecastINCY forecastALNY forecastASND forecastAll Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.